Concepedia

Jeroen Elassaiss‐Schaap

JE

13

Publications

6.8K

Citations

12

H-Index

2013

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California, San Francisco

University of California, Los Angeles

The University of Sydney

University of Pennsylvania

Jeroen Elassaiss‐Schaap is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and immunology.

ORCID

Top concepts

Publications per year

2013–2021

13

Publications

13

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.7K citations

, , +10

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, Soonmo Peter Kang, Drew Rasco et al. · Clinical Cancer Research · 2015 · 767 citations

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss‐Schaap, Richard Kefford et al. · Clinical Cancer Research · 2018 · 302 citations · Full text

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

Malidi Ahamadi, Tomoko Freshwater, Marita Prohn et al. · CPT Pharmacometrics & Systems Pharmacology · 2016 · 147 citations · Full text

, , +18

Rows per page

1–5 of 13